Zymeworks (FRA:ZA8) Change In Receivables : €32.69 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Zymeworks Change In Receivables?

Zymeworks's change in receivables for the quarter that ended in Mar. 2024 was €-10.55 Mil. It means Zymeworks's Accounts Receivable increased by €10.55 Mil from Dec. 2023 to Mar. 2024 .

Zymeworks's change in receivables for the fiscal year that ended in Dec. 2023 was €12.77 Mil. It means Zymeworks's Accounts Receivable declined by €12.77 Mil from Dec. 2022 to Dec. 2023 .

Zymeworks's Accounts Receivable for the quarter that ended in Mar. 2024 was €28.47 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Zymeworks's Days Sales Outstanding for the three months ended in Mar. 2024 was 281.55.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zymeworks's liquidation value for the three months ended in Mar. 2024 was €232.30 Mil.

Zymeworks Change In Receivables Historical Data

The historical data trend for Zymeworks's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Change In Receivables Chart

Zymeworks Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.65

-10.77

-0.24

-16.53

12.77

Zymeworks Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-31.30	16.71	-17.29	43.83	-10.55

Zymeworks Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €32.69 Mil.

Zymeworks (FRA:ZA8) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Zymeworks's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	28.473	/	9.228	*	91
=	281.55

2. In Ben Graham's calculation of liquidation value, Zymeworks's accounts receivable are only considered to be worth 75% of book value:

Zymeworks's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	317.443	-	106.493	+	0.75 * 28.473	+	0.5 * 0
=	232.30

Zymeworks Change In Receivables Related Terms

Thank you for viewing the detailed overview of Zymeworks's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Zymeworks (FRA:ZA8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (FRA:ZA8) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ZYME:USA

Address

108 Patriot Drive, Suite A, Middletown, DE, USA, 19709

Website

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks (FRA:ZA8) Headlines

No Headlines